Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the impact of the Private Provider Interface Agency (PPIA) program on quality of health care. The PPIA is a tuberculosis pilot program implemented in the private health sector of urban Patna in the state of Bihar, India.


Clinical Trial Description

By taking advantage of a randomized roll-out design of the PPIA program in urban Patna, this evaluation aims to determine the causal effects of the program on quality of health care among private sector health providers. The evaluation is embedded in an existing quality of care surveillance project that uses standardized patients to assess the quality of tuberculosis (TB) care in urban Patna. Below is a description of (1) the TB intervention implemented by the PPIA, (2) the quality of TB care (QuTUB) surveillance project, and (3) the randomized roll-out of the PPIA program among a subset of providers in order to isolate the impact of the program on quality of care.

The entire program and its implementation are external to the researchers. To better understand the impact of the program using an already approved design, the researchers use a stepped-wedge design that involves a sequential roll out of the program to a subset of providers over a period of time where the order of roll-out is randomized.

1. PPIA intervention: Between January 2014 and December 2016, the pilot PPIA program was independently implemented by the non-governmental organization World Health Partners (WHP) in urban Patna. In its role as the PPIA in Patna, WHP's aim is to strengthen existing efforts to control TB through engagement of the private health sector. Through this network, the objectives are to facilitate early and accurate diagnosis with proper notification of cases and to ensure appropriate treatment and treatment adherence to completion among TB patients in the private sector. This is done by establishing a network and engaging four types of private health sector actors who are of vital importance for TB advocacy and treatment efforts: (i) formal providers, who are qualified doctors at hospitals, nursing homes, or outpatient clinics who receive presumptive TB cases or treat TB cases, (ii) informal providers, who are non-allopathic providers or less than fully qualified practitioners, including practitioners of alternative medicines Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy and other practitioners with minimum or no qualifications, (iii) chemists/pharmacists with a drug license, medicine stock, and anti-TB drugs for sale, and (iv) diagnostic laboratories that conduct sputum smear microscopy and/or chest X-rays, and GeneXpert drug susceptibility testing. The pilot will serve as a model for private health sector involvement in national TB control and will be used to inform similar programs in other urban Indian settings.

2. Quality of care surveillance: The QuTUB project is a part of the PPIA monitoring efforts and runs in parallel to the program scale up and expansion. The objective of the QuTUB project is to capture levels of quality of care through standardized patients ("mystery shoppers" or "fake patients"), who are individuals recruited locally and trained to portray four different TB cases. Developed by a Technical Advisory Group and benchmarked against the Standards of TB Care of India, the cases were designed to reflect different stages of TB disease progression, some with previous interactions with the health system upon presentation to a health care provider. Outcomes captured by the standardized patients through an exit questionnaire given to them within 2 hours of their interaction with providers include: history questions asked by the provider, laboratory tests ordered, medicines dispensed or prescribed, and referrals made.

3. Randomized roll-out evaluation approach: In December 2014, WHP was interested in trying to further understand the causal impact of their program on diagnostic processes, and there was an opportunity to remove the selection bias and attribute differences in quality of care solely to the program by taking advantage of a randomized roll-out expansion plan of the PPIA program among a subset of providers. In collaboration with the PPIA Patna team, this study takes an intention-to-treat and instrumental variables evaluation approach through selective enrollment of a subset of providers in the second round of program scale-up across urban Patna. The researchers note that the subset of providers are those who were not purposively selected in the earlier round of enrollment and therefore may be those who see fewer TB patients, or those who were reluctant to enroll into the program during the first rounds of program expansion. Therefore, the impact of the program on this group may be different from among those who were enrolled previously. Under this approach, it was agreed that for the evaluation eligible formal providers would be engaged. For this, the researchers provided WHP with a list of 321 randomly selected providers among those who were not already enrolled at the beginning of 2015. Providers on this list were randomly allocated to two groups: one group (treatment) of 171 eligible formal providers would be sensitized and engaged, and the other group (control) of 150 eligible formal providers would not be engaged until the QuTUB study team is able to complete end-line data collection in 2016, after a year or more. Selection into program roll-out groups was randomized. The study group includes formal providers who would see a pulmonary TB case and self-reported low caseloads. Standardized patients are sent to both groups before any intervention for baseline measures of quality of care, and the standardized patients would return again before the control group begins to receive the intervention for an end-line measure. The entire intervention in Patna is implemented by the PPIA and is separate from the research team implementing the quality of care surveillance and evaluation. Care is taken to ensure that the evaluation team will be in the field independently of the implementation.

Analysis:

Intention-to-treat analysis and instrumental variables will be conducted after determining (i) that the treatment assignment can serve as a good instrument by: a strong correlation to the actual enrollment statuses of the providers regardless of treatment assignment, being uncorrelated with the outcomes, and only being connected to the outcomes through actual enrollment in the program, and (ii) balance at baseline between the treatment and control groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02874716
Study type Interventional
Source McGill University
Contact
Status Completed
Phase N/A
Start date January 2015
Completion date December 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2